Alexander D Cross Net Worth

The estimated Net Worth of Alexander D Cross is at least $9.16 Millón dollars as of 15 May 2013. Alexander Cross owns over 500 units of Ligand Pharmaceuticals stock worth over $9,161,196 and over the last 21 years Alexander sold LGND stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alexander Cross LGND stock SEC Form 4 insiders trading

Alexander has made over 1 trades of the Ligand Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Alexander bought 500 units of LGND stock worth $2,745 on 15 May 2013.

The largest trade Alexander's ever made was buying 500 units of Ligand Pharmaceuticals stock on 15 May 2013 worth over $2,745. On average, Alexander trades about 42 units every 0 days since 2003. As of 15 May 2013 Alexander still owns at least 88,866 units of Ligand Pharmaceuticals stock.

You can see the complete history of Alexander Cross stock trades at the bottom of the page.

What's Alexander Cross's mailing address?

Alexander's mailing address filed with the SEC is 4105 E. MADISON STREET, SUITE 320, SEATTLE, WA, 98112.

Insiders trading at Ligand Pharmaceuticals

Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... y Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.

What does Ligand Pharmaceuticals do?

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Complete history of Alexander Cross stock trades at Atossa Therapeutics Inc y Ligand Pharmaceuticals

Ligand Pharmaceuticals executives and stock owners

Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Higgins,
  Chief Executive Officer, Director
• Matthew Foehr,
  President, Chief Operating Officer
• Matthew Korenberg,
  Chief Financial Officer, Executive Vice President - Finance
• Charles Berkman,
  Senior Vice President, General Counsel, Secretary
• John L. Higgins,
  CEO & Exec. Director
• Matthew W. Foehr,
  Pres & COO
• Matthew E. Korenberg,
  Exec. VP of Fin. & CFO
• Charles S. Berkman J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Charles S. Berkman,
  Sr. VP, Gen. Counsel & Sec.
• Sarah Boyce,
  Independent Director
• John Kozarich,
  Non-Executive Independent Chairman of the Board
• Stephen Sabba,
  Independent Director
• Jason Aryeh,
  Independent Director
• Todd Davis,
  Independent Director
• Sunil Patel,
  Independent Director
• Nancy Gray,
  Independent Director
• John Lamattina,
  Independent Director
• Simon Latimer,
  Head of Investor Relations
• Patrick Lucy,
  Sr. VP & CBO Protein Expression Bus.
• Dr. Vincent D. Antle,
  Sr. VP of Technical Operations & QA - Capitsol
• Dr. Keith Marschke,
  Sr. VP of Biology & Scientific Affairs
• Audrey Warfield-Graham,
  Sr. VP of HR
• Todd Pettingill,
  Director of Corp. Devel.
• Patrick O'Brien,
  Sr. VP of Investor Relations
• Jason Haas,
  Director
• Corp Plc Elan,
  10% owner
• Andres Negro Vilar,
  Exe V-P, R & D, CSO
• Partners L P/Ilbiotechnolog...,
  
• Bruce Peacock,
  Director
• Zofia E Dziewanowska,
  VP, Clinical Research
• Partners L P/Ilbiotechnolog...,
  
• Melanie J Herman,
  Director of Accounting
• Nishan M De Silva,
  VP, Corporate Development
• David M Knott,
  10% owner
• Syed Kazmi,
  VP, Bus. Dev. & Strategic Plan
• Martin Meglasson,
  V-P, Discovery Research
• Pharmaceuticals Inc Ligand,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Steven J Burakoff,
  Director
• Brigette Roberts,
  Director
• Partners L P/Ilbiotechnolog...,
  
• John P Sharp,
  VP Finance and CFO
• Daniel S Loeb,
  Director
• Michael A Rocca,
  Director
• John Groom,
  Director
• Taylor Crouch,
  Sr. V-P, Ops & Pres. Int'l
• Partners L P/Ilbiotechnolog...,
  
• Jeffrey R Perry,
  Director
• Alexander D Cross,
  Director
• William A Petttit,
  Sr. V-P, HR and Administration
• Paul V Maier,
  Sr. V-P, CFO
• Warner R Broaddus,
  V-P, Gen. Counsel & Secy.
• Elizabeth M Greetham,
  Director
• Henry F Blissenbach,
  Director
• Irving S Johnson,
  Director
• Carl C Peck,
  Director
• Eric S Groves,
  V-P, Project Management
• Giambattista Aliprandi,
  Sr. VP, Tech., Sup & Intl Oper
• James J Litalien,
  Sr. V-P, Reg Affairs & Comp.
• David E Robinson,
  President & CEO
• Tod Mertes,
  V-P, Controller & Treasurer
• Jennifer R. Cochran,
  
• Octavio Espinoza,
  Chief Financial Officer
• Martine Zimmermann,
  Director
• Andrew Reardon,
  CLO & Secretary